Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Anti-asthmatic effect of fusarubin in an ovalbumin-induced asthmatic rat model

Jiajing Hong¹, Fuchun Wang¹, Dongyu Yang², Junming Kan³

¹College of Acupuncture and Massage, The Affiliated of Changchun University of Traditional Chinese Medicine, Changchun, Jilin 130117, China; ²Department of Traditional Chinese Medicine, The Affiliated of Changchun University of Traditional Chinese Medicine, ChaChangchun, Jilin 130117, China; ³College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin 130117, China.

For correspondence:- Junming Kan Email: 394327974@qq.com Tel:+8643186172513

Accepted: 24 December 2021 Published: 31 January 2022

Citation: Hong J, Wang F, Yang D, Kan J. Anti-asthmatic effect of fusarubin in an ovalbumin-induced asthmatic rat model. Trop J Pharm Res 2022; 21(1):87-92 doi: 10.4314/tjpr.v21i1.14

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the anti-asthmatic effect of fusarubin in an ovalbumin (OVA)-induced asthmatic rat model

Methods: A rat model of asthma was employed in this investigation. Ovalbumin (OVA) was used to sensitise rats, and the rats were then treated with fusarubin before the onset of asthma. Histology-based examinations were conducted to assess the impact of fusarubin on mucus secretion and migration of eosinophils into the lungs.

Results: The results showed that fusarubin significantly decreased ovalbumin-induced airway hyperresponsiveness {AHR levels of inflammatory cells and eosinophils in bronchoalveolar lavage fluid (BALF)}, when compared to the control group (p < 0.05). Furthermore, fusarubin markedly downregulated levels of OVA-stimulated pro-inflammatory cytokines in BAL fluid (p < 0.05).

Conclusion: Fusarubin may be used as a potential novel compound for the management of asthma.

Keywords: Asthma, Hypersensitivity, Fusarubin, Inflammatory cells, Eosinophil, Airway hyperresponsiveness, Bronchoalveolar lavage, Cytokines